KR101208192B1 - 유전자 전달을 위한 생물분해성 교차-연결된 양이온성다중-블록 공중합체 및 이의 제조 방법 - Google Patents

유전자 전달을 위한 생물분해성 교차-연결된 양이온성다중-블록 공중합체 및 이의 제조 방법 Download PDF

Info

Publication number
KR101208192B1
KR101208192B1 KR1020077012060A KR20077012060A KR101208192B1 KR 101208192 B1 KR101208192 B1 KR 101208192B1 KR 1020077012060 A KR1020077012060 A KR 1020077012060A KR 20077012060 A KR20077012060 A KR 20077012060A KR 101208192 B1 KR101208192 B1 KR 101208192B1
Authority
KR
South Korea
Prior art keywords
biodegradable
lpei
linked
cationic multi
cross
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020077012060A
Other languages
English (en)
Korean (ko)
Other versions
KR20070085500A (ko
Inventor
그레고리 슬로보드킨
마제드 마타르
제이슨 페웰
쿠르시드 안웨르
Original Assignee
익스프레션 제네틱스, 인코퍼레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 익스프레션 제네틱스, 인코퍼레이티드 filed Critical 익스프레션 제네틱스, 인코퍼레이티드
Publication of KR20070085500A publication Critical patent/KR20070085500A/ko
Application granted granted Critical
Publication of KR101208192B1 publication Critical patent/KR101208192B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/68—Polyesters containing atoms other than carbon, hydrogen and oxygen
    • C08G63/685—Polyesters containing atoms other than carbon, hydrogen and oxygen containing nitrogen
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/02—Polyamines
    • C08G73/0206—Polyalkylene(poly)amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Peptides Or Proteins (AREA)
KR1020077012060A 2004-11-03 2005-11-03 유전자 전달을 위한 생물분해성 교차-연결된 양이온성다중-블록 공중합체 및 이의 제조 방법 Expired - Fee Related KR101208192B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/981,135 2004-11-03
US10/981,135 US8057821B2 (en) 2004-11-03 2004-11-03 Biodegradable cross-linked cationic multi-block copolymers for gene delivery and methods of making thereof

Publications (2)

Publication Number Publication Date
KR20070085500A KR20070085500A (ko) 2007-08-27
KR101208192B1 true KR101208192B1 (ko) 2012-12-04

Family

ID=36262249

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020077012060A Expired - Fee Related KR101208192B1 (ko) 2004-11-03 2005-11-03 유전자 전달을 위한 생물분해성 교차-연결된 양이온성다중-블록 공중합체 및 이의 제조 방법

Country Status (7)

Country Link
US (2) US8057821B2 (enExample)
EP (1) EP1807054A4 (enExample)
JP (1) JP5436779B2 (enExample)
KR (1) KR101208192B1 (enExample)
CN (1) CN101094652B (enExample)
CA (1) CA2585974C (enExample)
WO (1) WO2006052649A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101992236B1 (ko) 2018-05-16 2019-06-24 가톨릭대학교 산학협력단 디셀레노디프로피오네이트의 양 말단에 폴리(입실론-카프로락톤)이 공유결합된 환원분해성 폴리(입실론-카프로락톤) 고분자, 이를 포함하는 항암용 조성물 및 약물 전달용 조성물

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7964571B2 (en) 2004-12-09 2011-06-21 Egen, Inc. Combination of immuno gene therapy and chemotherapy for treatment of cancer and hyperproliferative diseases
SI2730277T1 (sl) 2004-12-22 2020-07-31 Nitto Denko Corporation Nosilec zdravila in komplet za nosilec zdravila za zaviranje fibroze
US20120269886A1 (en) 2004-12-22 2012-10-25 Nitto Denko Corporation Therapeutic agent for pulmonary fibrosis
DE102005039154A1 (de) * 2005-08-17 2007-03-01 GÖPFERICH, Achim, Prof. Dr. Bioabbaubare Polymere für den Transport von Nukleinsäuren in Zellen
US9572886B2 (en) 2005-12-22 2017-02-21 Nitto Denko Corporation Agent for treating myelofibrosis
KR100825519B1 (ko) * 2007-01-05 2008-04-25 주식회사 바이오폴리메드 키토산 기재 고분자 접합체 및 그 제조방법
WO2008106186A2 (en) * 2007-02-28 2008-09-04 Serina Therapeutics, Inc. Activated polyoxazolines and compositions comprising the same
TWI407971B (zh) 2007-03-30 2013-09-11 Nitto Denko Corp Cancer cells and tumor-related fibroblasts
WO2009009441A2 (en) 2007-07-06 2009-01-15 Cedars-Sinai Medical Center Self-assembling complex for targeting chemical agents to cells
US9144546B2 (en) 2007-08-06 2015-09-29 Clsn Laboratories, Inc. Nucleic acid-lipopolymer compositions
WO2009036368A2 (en) 2007-09-14 2009-03-19 Nitto Denko Corporation Drug carriers
US20090130752A1 (en) * 2007-11-07 2009-05-21 University Of Utah Research Foundation Biodegradable poly(disulfide amine)s for gene delivery
US20100285111A1 (en) * 2007-11-09 2010-11-11 Northeastern University Self-assembling micelle-like nanoparticles for systemic gene delivery
US20090171455A1 (en) * 2007-12-31 2009-07-02 Boston Scientific Scimed, Inc. Biodegradable polymers
DK3042922T3 (en) * 2008-01-11 2017-10-23 Serina Therapeutics Inc MULTIFUNCTIONAL FORMS OF POLYOXAZOLINE COLPOLYMERS AND PHARMACEUTICAL COMPOSITIONS INCLUDING THE SAME
FR2928373B1 (fr) * 2008-03-05 2010-12-31 Centre Nat Rech Scient Polymere derive de la polyethylenimine lineaire pour le transfert de gene.
CN102027043A (zh) * 2008-03-14 2011-04-20 艾根股份有限公司 生物可降解的交联支链聚(亚烷基亚胺)
US8575123B2 (en) * 2008-04-11 2013-11-05 Tekmira Pharmaceuticals Corporation Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
WO2010085665A2 (en) 2009-01-23 2010-07-29 Cedars-Sinai Medical Center Targeted delivery system
KR101132413B1 (ko) * 2009-05-06 2012-04-03 서울대학교산학협력단 Ｓａｒｓ 백신 나노전달체
WO2010132879A2 (en) 2009-05-15 2010-11-18 The Johns Hopkins University Multicomponent degradable cationic polymers
CN101585921B (zh) * 2009-06-18 2010-12-01 天津大学 温度敏感聚乙烯亚胺-接枝-聚丙烯酸寡乙二醇酯嵌段共聚物及制备方法和应用
CN102575204B (zh) * 2009-10-23 2015-02-25 荷兰联合利华有限公司 染料聚合物
CN101812178B (zh) * 2010-04-20 2012-07-04 武汉大学 还原敏感性聚乙烯亚胺衍生物及其制备方法和应用
WO2011143602A1 (en) * 2010-05-14 2011-11-17 The Sun Products Corporation Polymer-containing cleaning compositions and methods of production and use thereof
BR112012030306A2 (pt) * 2010-06-25 2019-09-24 Toray Industries polímero solúvel em água, complexo de nanopartícula solúvel em água, método de produção de um complexo de nanopartícula solúvel em água e reagente
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CA2821992A1 (en) 2010-10-01 2012-04-05 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CN102174184B (zh) * 2011-01-14 2012-11-21 中国科学院广州生物医药与健康研究院 一种生物可降解的聚合物及其制备方法以及核酸药物运输载体
DE12722942T1 (de) 2011-03-31 2021-09-30 Modernatx, Inc. Freisetzung und formulierung von manipulierten nukleinsäuren
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2755636A1 (en) 2011-09-16 2014-07-23 The Charlotte-Mecklenburg Hospital Authority D/B/A Carolinas Healthcare System Amphiphilic cationic polymers for the delivery of therapeutic agents
HRP20220250T1 (hr) 2011-10-03 2022-04-29 Modernatx, Inc. Modificirani nukleozidi, nukleotidi i nukleinske kiseline, te njihove uporabe
SI2791160T1 (sl) 2011-12-16 2022-07-29 Modernatx, Inc. Sestave modificirane MRNA
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
AU2013243952A1 (en) 2012-04-02 2014-10-30 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
HK1206612A1 (en) 2012-04-02 2016-01-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of secreted proteins
US20130337067A1 (en) 2012-06-15 2013-12-19 The Royal Institution For The Advancement Of Learning/Mcgill University Non-viral nanoparticle-based delivery system
PT2880160T (pt) 2012-08-03 2018-12-17 Cedars Sinai Medical Center Isolamento de mutantes que aumentam o tráfego de proteínas para administração de fármacos
WO2014056414A1 (zh) 2012-10-10 2014-04-17 四川大学 一种还原刺激响应型基因载体系统及其制备和应用
CN103305549B (zh) * 2013-06-19 2015-04-22 四川大学 具有多重氧化还原刺激响应的纳米粒子基因载体系统及其制备方法和应用
KR101452819B1 (ko) 2012-11-01 2014-10-23 국립암센터 환원제 반응형 이황화물 연결자 함유 고분자-광감각제 결합체 및 이를 포함하는 형광 영상 진단 및 광역학 치료용 조성물
SMT202200337T1 (it) 2012-11-26 2022-09-14 Modernatx Inc Rna modificato al livello del terminale
AU2013374345A1 (en) 2013-01-17 2015-08-06 Moderna Therapeutics, Inc. Signal-sensor polynucleotides for the alteration of cellular phenotypes
EP2968391A1 (en) 2013-03-13 2016-01-20 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
EP2971010B1 (en) 2013-03-14 2020-06-10 ModernaTX, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
HUE056760T2 (hu) 2013-07-11 2022-03-28 Modernatx Inc A CRISPR-hez kapcsolódó fehérjéket és a szintetikus SGRNS-ket kódoló szintetikus polinukleotidokat tartalmazó készítmények és felhasználási módjaik
AU2014315287A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Chimeric polynucleotides
EP3041938A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Circular polynucleotides
US10323076B2 (en) 2013-10-03 2019-06-18 Modernatx, Inc. Polynucleotides encoding low density lipoprotein receptor
WO2015095351A1 (en) 2013-12-19 2015-06-25 Novartis Ag LEPTIN mRNA COMPOSITIONS AND FORMULATIONS
RU2682335C2 (ru) 2014-01-17 2019-03-19 Сидарс-Синай Медикал Сентр Рецептор-направленные конструкции и их применение
AU2015240460A1 (en) 2014-04-04 2016-09-15 Cedars-Sinai Medical Center Targeting trastuzumab-resistant HER2+breast cancer with a HER3-targeting nanoparticle
CN104109248B (zh) * 2014-06-20 2017-02-01 南开大学 基于桥式双环糊精主客体诱导聚集构筑的聚集体及其应用
WO2016011226A1 (en) 2014-07-16 2016-01-21 Moderna Therapeutics, Inc. Chimeric polynucleotides
WO2016014846A1 (en) 2014-07-23 2016-01-28 Moderna Therapeutics, Inc. Modified polynucleotides for the production of intrabodies
CN104356395B (zh) * 2014-11-12 2016-08-17 苏州大学 一种阳离子化丝素蛋白、制备方法及其应用
WO2016077625A1 (en) * 2014-11-12 2016-05-19 Stayton Patrick S Stabilized polymeric carriers for therapeutic agent delivery
CN105012957B (zh) * 2015-07-03 2019-03-22 上海交通大学 一种交联型聚乙烯亚胺作为肿瘤蛋白抗原疫苗载体的用途
US20180256730A1 (en) * 2015-09-16 2018-09-13 University Of Utah Research Foundation A polymeric carrier for delivery of a payload to a cell
DE102017003004A1 (de) * 2017-03-23 2018-09-27 Friedrich-Schiller-Universität Jena Kationische Polymere mit D-Fructose-Substituenten
EP3625345B1 (en) 2017-05-18 2023-05-24 ModernaTX, Inc. Modified messenger rna comprising functional rna elements
CA3063723A1 (en) 2017-05-18 2018-11-22 Modernatx, Inc. Polynucleotides encoding tethered interleukin-12 (il12) polypeptides and uses thereof
MA49395A (fr) 2017-06-14 2020-04-22 Modernatx Inc Polynucléotides codant pour le facteur viii de coagulation
US20200208152A1 (en) 2017-09-08 2020-07-02 Mina Therapeutics Limited Stabilized sarna compositions and methods of use
WO2019104195A1 (en) 2017-11-22 2019-05-31 Modernatx, Inc. Polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits for the treatment of propionic acidemia
WO2019104160A2 (en) 2017-11-22 2019-05-31 Modernatx, Inc. Polynucleotides encoding phenylalanine hydroxylase for the treatment of phenylketonuria
JP7423522B2 (ja) 2017-11-22 2024-01-29 モダーナティエックス・インコーポレイテッド 尿素サイクル異常症の治療のためのオルニチントランスカルバミラーゼをコードするポリヌクレオチド
US11802146B2 (en) 2018-01-05 2023-10-31 Modernatx, Inc. Polynucleotides encoding anti-chikungunya virus antibodies
WO2019165583A1 (zh) * 2018-02-27 2019-09-06 苏州大学张家港工业技术研究院 一种可逆自修复环氧树脂及其制备与回收重塑方法
US11566246B2 (en) 2018-04-12 2023-01-31 Mina Therapeutics Limited SIRT1-saRNA compositions and methods of use
US20210148918A1 (en) * 2018-04-17 2021-05-20 Purdue Research Foundation Modifying surface of a live cell and the uses thereof
MA52709A (fr) 2018-05-23 2021-03-31 Modernatx Inc Administration d'adn
WO2020023390A1 (en) 2018-07-25 2020-01-30 Modernatx, Inc. Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders
EP3833762A4 (en) 2018-08-09 2022-09-28 Verseau Therapeutics, Inc. Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof
CN110859969B (zh) * 2018-08-28 2022-01-11 上海市第十人民医院 聚乙烯亚胺修饰的荧光素钠造影剂及其制备方法和应用
WO2020047201A1 (en) 2018-09-02 2020-03-05 Modernatx, Inc. Polynucleotides encoding very long-chain acyl-coa dehydrogenase for the treatment of very long-chain acyl-coa dehydrogenase deficiency
MA53608A (fr) 2018-09-13 2021-07-21 Modernatx Inc Polynucléotides codant pour les sous-unités e1-alpha, e1-beta et e2 du complexe alpha-cétoacide déshydrogénase à chaîne ramifiée pour le traitement de la leucinose
MA53609A (fr) 2018-09-13 2021-07-21 Modernatx Inc Polynucléotides codant la glucose-6-phosphatase pour le traitement de la glycogénose
US20220401584A1 (en) 2018-09-14 2022-12-22 Modernatx, Inc. Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide a1 for the treatment of crigler-najjar syndrome
US20220152225A1 (en) 2018-09-27 2022-05-19 Modernatx, Inc. Polynucleotides encoding arginase 1 for the treatment of arginase deficiency
US20220211740A1 (en) 2019-04-12 2022-07-07 Mina Therapeutics Limited Sirt1-sarna compositions and methods of use
EP3965797A1 (en) 2019-05-08 2022-03-16 AstraZeneca AB Compositions for skin and wounds and methods of use thereof
BR112022011143A2 (pt) * 2019-12-17 2022-08-23 Univ Gent Vetores não virais compreendendo polipropilenoimina
JP2023527875A (ja) 2020-06-01 2023-06-30 モダーナティエックス・インコーポレイテッド フェニルアラニンヒドロキシラーゼバリアント及びその使用
CA3199784A1 (en) 2020-11-13 2022-05-19 Modernatx, Inc. Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis
US20240226025A1 (en) 2021-03-24 2024-07-11 Modernatx, Inc. Polynucleotides encoding methylmalonyl-coa mutase for the treatment of methylmalonic acidemia
WO2022204390A1 (en) 2021-03-24 2022-09-29 Modernatx, Inc. Lipid nanoparticles containing polynucleotides encoding phenylalanine hydroxylase and uses thereof
WO2022204370A1 (en) 2021-03-24 2022-09-29 Modernatx, Inc. Lipid nanoparticles and polynucleotides encoding ornithine transcarbamylase for the treatment of ornithine transcarbamylase deficiency
WO2022204380A1 (en) 2021-03-24 2022-09-29 Modernatx, Inc. Lipid nanoparticles containing polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits and uses thereof
WO2022204371A1 (en) 2021-03-24 2022-09-29 Modernatx, Inc. Lipid nanoparticles containing polynucleotides encoding glucose-6-phosphatase and uses thereof
JP2024511092A (ja) 2021-03-26 2024-03-12 ミナ セラピューティクス リミテッド ＴＭＥＭ１７３ｓａＲＮＡ組成物及び使用方法
US20240384277A1 (en) 2021-06-15 2024-11-21 Modernatx, Inc. Engineered polynucleotides for cell-type or microenvironment-specific expression
WO2022271776A1 (en) 2021-06-22 2022-12-29 Modernatx, Inc. Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide a1 for the treatment of crigler-najjar syndrome
EP4408871A1 (en) 2021-10-01 2024-08-07 ModernaTX, Inc. Polynucleotides encoding relaxin for the treatment of fibrosis and/or cardiovascular disease
WO2023099884A1 (en) 2021-12-01 2023-06-08 Mina Therapeutics Limited Pax6 sarna compositions and methods of use
WO2023170435A1 (en) 2022-03-07 2023-09-14 Mina Therapeutics Limited Il10 sarna compositions and methods of use
US20250221931A1 (en) 2022-03-25 2025-07-10 Modernatx, Inc. Polynucleotides encoding fanconi anemia, complementation group proteins for the treatment of fanconi anemia
CN114920859B (zh) * 2022-05-11 2023-09-26 宁夏医科大学总医院 5-氟尿嘧啶-1-丁酰基-β-环糊精第二面衍生物及制备方法及其应用
TW202412818A (zh) 2022-07-26 2024-04-01 美商現代公司 用於暫時控制表現之經工程化多核苷酸
WO2024103225A1 (zh) * 2022-11-14 2024-05-23 林桂孜 一种阳离子聚酯及其制备方法和应用
EP4634388A1 (en) 2022-12-14 2025-10-22 Providence Therapeutics Holdings Inc. Compositions and methods for infectious diseases
WO2024134199A1 (en) 2022-12-22 2024-06-27 Mina Therapeutics Limited Chemically modified sarna compositions and methods of use
WO2024197033A1 (en) 2023-03-21 2024-09-26 Modernatx, Inc. Polynucleotides encoding relaxin for the treatment of heart failure
WO2024229321A1 (en) 2023-05-03 2024-11-07 Modernatx, Inc. Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis
WO2025072482A1 (en) 2023-09-27 2025-04-03 Modernatx, Inc. Immunoglobulin a protease polypeptides, polynucleotides, and uses thereof
WO2025255199A1 (en) 2024-06-05 2025-12-11 Modernatx, Inc. Argininosuccinate synthase 1 and argininosuccinate lyase polypeptides and polynucleotides and uses thereof
CN119192568A (zh) * 2024-10-11 2024-12-27 湖北中烟工业有限责任公司 还原敏感型超分子基因载体、其制备方法及应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS592464B2 (ja) * 1980-04-16 1984-01-18 電気化学工業株式会社 熱可塑性樹脂組成物
US6359054B1 (en) 1994-11-18 2002-03-19 Supratek Pharma Inc. Polynucleotide compositions for intramuscular administration
US5733462A (en) * 1996-10-03 1998-03-31 Cytec Technology Corp. Cationic water-soluble polymer precipitation in salt solutions
US6333051B1 (en) 1998-09-03 2001-12-25 Supratek Pharma, Inc. Nanogel networks and biological agent compositions thereof
CA2353552A1 (en) * 1998-12-04 2000-06-15 California Institute Of Technology Supramolecular complexes containing therapeutic agents
DE19933024C2 (de) * 1999-07-15 2003-03-13 Medinnova Ges Med Innovationen Kationische Blockcopolymere
CN1433478A (zh) * 1999-12-30 2003-07-30 诺瓦提斯公司 用于基因治疗的新的胶体合成载体
US20040142474A1 (en) * 2000-09-14 2004-07-22 Expression Genetics, Inc. Novel cationic lipopolymer as a biocompatible gene delivery agent
US6696038B1 (en) * 2000-09-14 2004-02-24 Expression Genetics, Inc. Cationic lipopolymer as biocompatible gene delivery agent
US6890556B1 (en) * 2001-02-14 2005-05-10 Northwestern University Controlled surface-associated delivery of genes and oligonucleotides
US6652886B2 (en) 2001-02-16 2003-11-25 Expression Genetics Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents
US6521340B2 (en) * 2001-03-15 2003-02-18 Norman B. Rainer Sulfur-containing aliphatic polymer for the selective absorption of dissolved metal species
US7060498B1 (en) 2001-11-28 2006-06-13 Genta Salus Llc Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers
US20030215395A1 (en) * 2002-05-14 2003-11-20 Lei Yu Controllably degradable polymeric biomolecule or drug carrier and method of synthesizing said carrier
GB0221942D0 (en) * 2002-09-20 2002-10-30 Univ Strathclyde Drug delivery

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101992236B1 (ko) 2018-05-16 2019-06-24 가톨릭대학교 산학협력단 디셀레노디프로피오네이트의 양 말단에 폴리(입실론-카프로락톤)이 공유결합된 환원분해성 폴리(입실론-카프로락톤) 고분자, 이를 포함하는 항암용 조성물 및 약물 전달용 조성물

Also Published As

Publication number Publication date
US8057821B2 (en) 2011-11-15
EP1807054A2 (en) 2007-07-18
US20060093674A1 (en) 2006-05-04
US20120009145A1 (en) 2012-01-12
WO2006052649A3 (en) 2006-09-14
CN101094652A (zh) 2007-12-26
CA2585974C (en) 2017-07-04
KR20070085500A (ko) 2007-08-27
WO2006052649A2 (en) 2006-05-18
CA2585974A1 (en) 2006-05-18
CN101094652B (zh) 2011-05-25
EP1807054A4 (en) 2008-07-23
JP2008519128A (ja) 2008-06-05
JP5436779B2 (ja) 2014-03-05
US8445017B2 (en) 2013-05-21

Similar Documents

Publication Publication Date Title
KR101208192B1 (ko) 유전자 전달을 위한 생물분해성 교차-연결된 양이온성다중-블록 공중합체 및 이의 제조 방법
US6652886B2 (en) Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents
US8431545B2 (en) Copolymer including uncharged hydrophilic block and cationic polyamino acid block having hydrophobic group in part of side chains, and use thereof
US20030147958A1 (en) Biodegradable multi-block copolymers of poly(amino acid)s and poly(ethylene glycol) for the delivery of bioactive agents
US20100004315A1 (en) Biodegradable Cross-Linked Branched Poly(Alkylene Imines)
US8906503B2 (en) Fine particles of crystalline polyol, and method of preparing same
CN115417889A (zh) 一种l-4-二羟基硼苯丙氨酸-n-羧酸内酸酐单体和聚氨基酸及其制备方法和应用
Dong et al. Functional amphiphilic poly (2-oxazoline) block copolymers as drug carriers: the relationship between structure and drug loading capacity
Huang et al. Polypeptide–poly (ethylene glycol) miktoarm star copolymers with a fluorescently labeled core: Synthesis, delivery and imaging of siRNA
WO2023240505A1 (zh) 一种l-4-二羟基硼苯丙氨酸-n-羧酸内酸酐单体和聚氨基酸及其制备方法和应用
KR20140019214A (ko) 폴리에틸렌글리콜-폴리락트산-폴리에틸렌이민 양이온성 공중합체, 이의 제조방법 및 상기 공중합체를 포함하는 약물 전달용 조성물
US20060275250A1 (en) Reactive polymers and copolymers, method of their preparation and their use
CN107266384B (zh) 基于2-氨基十六烷酸的n-羧基内酸酐单体和聚氨基酸及其制备方法
Liang et al. High-molecular-weight polyethyleneimine conjuncted pluronic for gene transfer agents
Yi et al. Diol glycidyl ether-bridged cyclens: preparation and their applications in gene delivery
Choi et al. Characterization of linear polymer-dendrimer block copolymer/plasmid DNA complexes: formation of core-shell type nanoparticles with DNA and application to gene delivery in vitro
Zhong et al. Structurally well-defined copolymers of poly (ethylene glycol) and low molecular weight linear polyethylenimine as vectors for gene delivery
Coué et al. Novel thermo-responsive polymers based on bioreducible poly (amidoamine) s

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20151030

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20161028

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20171027

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

FPAY Annual fee payment

Payment date: 20191029

Year of fee payment: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 11

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20231129

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20231129